Bristol-Myers Squibb Co vs Lennar Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.73 (market cap $129.94B), while Lennar Corporation trades at $85.65 (market cap $21.05B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.2× Lennar Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | LEN | |
|---|---|---|
Market Cap | $129.94B | $21.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $142.40 |
52-Week Low | $42.60 | $81.84 |
Enterprise Value | $163.92B | $24.93B |
Dividend Yield | 3.96% | 2.28% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Lennar (LEN) trades at $85.6, down 2.93% on the day, with a bearish technical signal from moving averages and recent earnings misses. The stock appears fundamentally undervalued with a P/E of 13.72 and P/S of 0.66, but faces headwinds from declining revenue and net income margins, which fell to 4.93% in 2025. A new housing affordability law offers a potential catalyst, while high mortgage rates and competitive pressures from disruptors like Boxabl present challenges.
The outlook is mixed; valuation metrics suggest upside potential, but weakening profitability and a bearish technical trend warrant caution. The consensus price target of $84.30 implies limited near-term growth, with investment opportunity hinging on a housing market recovery and execution against margin pressures.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →